Retifanlimab + Tuparstobart + Verzistobart

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

Conditions

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma

Trial Timeline

Nov 8, 2023 → Apr 30, 2027

NCT ID

NCT06056895

About Retifanlimab + Tuparstobart + Verzistobart

Retifanlimab + Tuparstobart + Verzistobart is a phase 2 stage product being developed by Incyte for Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8. The current trial status is active. This product is registered under clinical trial identifier NCT06056895. Target conditions include Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma.

What happened to similar drugs?

1 of 20 similar drugs in Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 were approved

Approved (1) Terminated (1) Active (18)

✅DurvalumabAstraZenecaApproved

🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3

🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3

🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3

🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3

🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06056895	Phase 2	Active	Nov 8, 2023	Apr 30, 2027	Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

Competing Products

20 competing products in Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	26
zolbetuximab	Astellas Pharma	Pre-clinical	30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44
zolbetuximab	Astellas Pharma	Pre-clinical	33
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	47
ASP1948	Astellas Pharma	Phase 1	29
Lenvatinib	Eisai	Phase 2	35
Lenvatinib	Eisai	Phase 1	29
Nivolumab + Everolimus	Ono Pharmaceutical	Phase 3	40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + Cetuximab	Ono Pharmaceutical	Phase 1	33
SHR-4602	Jiangsu Hengrui Medicine	Phase 2	42
SHR-1210 + Apatinib + Sorafenib	Jiangsu Hengrui Medicine	Phase 3	40
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358	Jiangsu Hengrui Medicine	Phase 1/2	39
Camrelizumab + HAIC + TKI	Jiangsu Hengrui Medicine	Phase 2	31
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811	Jiangsu Hengrui Medicine	Phase 3	44
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin	AbbVie	Phase 2	42